Aging Brain Changes, Executive Dysfunction and Depression

NCT00918684, Phase 4, Completed, Weill Medical College of Cornell University; results first posted 2017-05-12

Trial 11

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Field	Value	Source
Title	Aging Brain Changes, Executive Dysfunction and Depression	ClinicalTrials.gov
NCT number	NCT00918684	ClinicalTrials.gov
Status	Completed	ClinicalTrials.gov
Phases	Phase 4	ClinicalTrials.gov
Enrollment	116 participants, actual	ClinicalTrials.gov
Lead sponsor	Weill Medical College of Cornell University	ClinicalTrials.gov
Conditions	Depression	ClinicalTrials.gov
Interventions	Escitalopram	ClinicalTrials.gov
First posted	2009-06-11	ClinicalTrials.gov
Last updated	2017-05-12	ClinicalTrials.gov
Results first posted	2017-05-12	ClinicalTrials.gov

Registered outcomes 3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description	Source
Primary	Hamilton Depression Rating Scale.	14 weeks (12th week of treatment)	A published and widely-used scale for rating depression severity, the Hamilton Depression Rating Scale 24 item total scores range from 0-76. Higher scores indicate greater severity of depression. Total scores are reported with no subscales.	ClinicalTrials.gov
Primary	WHODAS-II Disability Scale	14 weeks (12th week of treatment)	A disability rating scale published by the World Health Organization, the WHODAS II total scores can range from 0-100. Higher scores indicate greater severity of disability. Total scores are reported with no subscales.	ClinicalTrials.gov
Primary	Stroop Color-Word Test	14 weeks (12th week of treatment)	A published and widely used executive dysfunction test, the Stroop Color-Word total scores can range from 0-100. Higher scores indicate better memory functioning (no cognitive impairment). Total scores are reported with no subscales.	ClinicalTrials.gov

Outcomes 3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as	Source
PRIMARY	Hamilton Depression Rating Scale.	14 weeks (12th week of treatment)	units on a scale	MEAN	ClinicalTrials.gov
PRIMARY	WHODAS-II Disability Scale	14 weeks (12th week of treatment)	units on a scale	MEAN	ClinicalTrials.gov
PRIMARY	Stroop Color-Word Test	14 weeks (12th week of treatment)	units on a scale	MEAN	ClinicalTrials.gov

Results by group 3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units	Source
Hamilton Depression Rating Scale.	Escitalopram	8.09	Standard Deviation 5.93	units on a scale	ClinicalTrials.gov
WHODAS-II Disability Scale	Escitalopram	31.43	Standard Deviation 9.14	units on a scale	ClinicalTrials.gov
Stroop Color-Word Test	Escitalopram	33.63	Standard Deviation 10.2	units on a scale	ClinicalTrials.gov

Participant flow 6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants	Source
Two Week Drug Washout and Placebo Phase	STARTED	Escitalopram	106	ClinicalTrials.gov
Two Week Drug Washout and Placebo Phase	COMPLETED	Escitalopram	90	ClinicalTrials.gov
Two Week Drug Washout and Placebo Phase	NOT COMPLETED	Escitalopram	16	ClinicalTrials.gov
Treatment Phase	STARTED	Escitalopram	90	ClinicalTrials.gov
Treatment Phase	COMPLETED	Escitalopram	65	ClinicalTrials.gov
Treatment Phase	NOT COMPLETED	Escitalopram	25	ClinicalTrials.gov

Adverse events 61

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events	Source
other	Abdominal pain	Gastrointestinal disorders	Escitalopram	2	90	2	ClinicalTrials.gov
other	Anorgasmia	Psychiatric disorders	Escitalopram	1	90	1	ClinicalTrials.gov
other	Anxiety	Psychiatric disorders	Escitalopram	5	90	5	ClinicalTrials.gov
other	Atrial fibrillation	Cardiac disorders	Escitalopram	1	90	1	ClinicalTrials.gov
other	Prolonged bleeding after a cut	Blood and lymphatic system disorders	Escitalopram	1	90	1	ClinicalTrials.gov
other	Bruising	Injury, poisoning and procedural complications	Escitalopram	1	90	1	ClinicalTrials.gov
other	Cataract	Eye disorders	Escitalopram	1	90	1	ClinicalTrials.gov
other	Constipation	Gastrointestinal disorders	Escitalopram	2	90	2	ClinicalTrials.gov
other	Cough	Respiratory, thoracic and mediastinal disorders	Escitalopram	1	90	1	ClinicalTrials.gov
other	Dehydration	Metabolism and nutrition disorders	Escitalopram	1	90	1	ClinicalTrials.gov
other	Diarrhea	Gastrointestinal disorders	Escitalopram	3	90	3	ClinicalTrials.gov
other	Dizziness	Nervous system disorders	Escitalopram	5	90	5	ClinicalTrials.gov
other	Dry Mouth	Gastrointestinal disorders	Escitalopram	1	90	1	ClinicalTrials.gov
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	Escitalopram	1	90	1	ClinicalTrials.gov
other	Edema cerebral	Nervous system disorders	Escitalopram	1	90	1	ClinicalTrials.gov
other	Edema limbs	General disorders	Escitalopram	1	90	1	ClinicalTrials.gov
other	Fall	Injury, poisoning and procedural complications	Escitalopram	11	90	15	ClinicalTrials.gov
other	Gastritis	Gastrointestinal disorders	Escitalopram	1	90	1	ClinicalTrials.gov
other	Gastroesophageal reflux disease	Gastrointestinal disorders	Escitalopram	2	90	2	ClinicalTrials.gov
other	Prolonged gum bleeding	Gastrointestinal disorders	Escitalopram	1	90	1	ClinicalTrials.gov

Adverse event totals 3

The totals the trial posted for each group.

Total	Group	Affected	At risk	Source
Total, all-cause mortality	Escitalopram	0	90	ClinicalTrials.gov
Total, other adverse events	Escitalopram	55	90	ClinicalTrials.gov
Total, serious adverse events	Escitalopram	6	90	ClinicalTrials.gov

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source

Grants 1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
R01MH065653	Aging, White Matter Changes, Executive Dysfunction and Depression	YOUNG, ROBERT C.	WEILL MEDICAL COLL OF CORNELL UNIV	NATIONAL INSTITUTE OF MENTAL HEALTH	2003 to 2007	NIH RePORTER

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source

Tests 1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source
Stroop Color-Word Test	Primary outcome	ConductCognition

Source 5

Field	Value	Source
Release	trials-2026-11-12-0.4.0	ClinicalTrials.gov
Release manifest SHA-256	0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4	ClinicalTrials.gov
Registry capture	2026-11-12	ClinicalTrials.gov
Results copy, AACT	2026-03-23	ClinicalTrials.gov
NIH clinical studies file	2026-11-13	ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)